Effector t cells in multiple sclerosis

Cold Spring Harbor Perspectives in Medicine

Volumn 8, Issue 4, 2018, Pages

  Kaskow, Belinda J ^a   Baecher Allan, Clare ^b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MYELIN;

ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL POPULATION; CYTOLOGY; EFFECTOR CELL; HUMAN; MULTIPLE SCLEROSIS; NONHUMAN; PATHOLOGY; REGULATORY MECHANISM; T LYMPHOCYTE; TH1 CELL; TH17 CELL; ANIMAL; CENTRAL NERVOUS SYSTEM; IMMUNOLOGY; IMMUNOMODULATION;

ANIMALS; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CENTRAL NERVOUS SYSTEM; HUMANS; MULTIPLE SCLEROSIS; NEUROIMMUNOMODULATION; TH1 CELLS; TH17 CELLS;

EID: 85045004888     PISSN: None     EISSN: 21571422     Source Type: Journal    
DOI: 10.1101/cshperspect.a029025     Document Type: Article

References (139)

1. Allegretta M, Nicklas JA, Sriram S, Albertini RJ. 1990. T cells responsive to myelin basic protein in patients with multiple sclerosis. Science 247: 718–721.
2. Aloisi F, Ria F, Adorini L. 2000. Regulation of T-cell responses by CNS antigen-presenting cells: Different roles for microglia and astrocytes. Immunol Today 21: 141– 147.
3. Andreadou E, Kemanetzoglou E, Brokalaki C, Evangelopou-los ME, Kilidireas C, Rombos A, Stamboulis E. 2013. Demyelinating disease following anti-TNFa treatment: A causal or coincidental association? Report of four cases and review of the literature. Case Rep Neurol Med 2013: 671935.
4. + T cells bear pathogenetic potential in multiple sclerosis. Brain 134: 542–554.
5. Arellano G, Ottum PA, Reyes LI, Burgos PI, Naves R. 2015. Stage-specific role of interferon-γ in experimental autoimmune encephalomyelitis and multiple sclerosis. Front Immunol 6: 492.
6. Arnason BG, Jankovic BD, Waksman BH, Wennersten C. 1962. Role of the thymus in immune reactions in rats. II: Suppressive effect of thymectomy at birth on reactions of delayed (cellular) hypersensitivity and the circulating small lymphocyte. J Exp Med 116: 177–186.
7. Axtell RC, Raman C. 2012. Janus-like effects of type I interferon in autoimmune diseases. Immunol Rev 248: 23–35.
8. Axtell RC, de Jong BA, Boniface K, van der Voort LF, Bhat R, De Sarno P, Naves R, Han M, Zhong F, Castellanos JG, et al. 2010. T helper type 1 and 17 cells determine efficacy of interferon-β in multiple sclerosis and experimental encephalomyelitis. Nat Med 16: 406–412.
9. + T cells dominate the T cell infiltrate in active multiple sclerosis lesions as shown by micromanipulation and single cell polymerase chain reaction. J Exp Med 192: 393–404.
10. Barcellos LF, Oksenberg JR, Begovich AB, Martin ER, Schmidt S, Vittinghoff E, Goodin DS, Pelletier D, Lincoln RR, Bucher P, et al. 2003. HLA-DR2 dose effect on susceptibility to multiple sclerosis and influence on disease course. Am J Hum Genet 72: 710–716.
11. + regulatory T-cell function is deficient during acute exacerbation of multiple sclerosis. J Autoimmunity 36: 115–124.
12. Ben-Nun A, Wekerle H, Cohen IR. 1981. The rapid isolation of clonable antigen-specific T lymphocyte lines capable of mediating autoimmune encephalomyelitis. Eur J Immunol 11: 195–199.
13. + T cell responses against myelin determinants in multiple sclerosis and healthy individuals. Eur J Immunol 38: 1889–1899.
14. + T-cell response. Nat Rev Immunol 4: 595–602.
15. lo Tregs in multiple sclerosis and in response to IL-6. J Immunol 194: 2180–2189.
16. Bielekova B, Goodwin B, Richert N, Cortese I, Kondo T, Afshar G, Gran B, Eaton J, Antel J, Frank JA, et al. 2000. Encephalitogenic potential of the myelin basic protein peptide (amino acids 83-99) in multiple sclerosis: Results of a phase II clinical trial with an altered peptide ligand. Nat Med 6: 1167–1175.
17. Bitsch A, Schuchardt J, Bunkowski S, Kuhlmann T, Bruck W. 2000. Acute axonal injury in multiple sclerosis. Correlation with demyelination and inflammation. Brain 123: 1174–1183.
18. Bromley SK, Thomas SY, Luster AD. 2005. Chemokine receptor CCR7 guides T cell exit from peripheral tissues and entry into afferent lymphatics. Nat Immunol 6: 895–901.
19. Brucklacher-Waldert V, Stuerner K, Kolster M, Wolthausen J, Tolosa E. 2009. Phenotypical and functional characterization of T helper 17 cells in multiple sclerosis. Brain 132: 3329–3341.
20. Brynedal B, Duvefelt K, Jonasdottir G, Roos IM, Akesson E, Palmgren J, Hillert J. 2007. HLA-A confers an HLA-DRB1 independent influence on the risk of multiple sclerosis. PLoS ONE 2: e664.
21. Burns J, Rosenzweig A, Zweiman B, Lisak RP. 1983. Isolation of myelin basic protein-reactive T-cell lines from normal human blood. Cell Immunol 81: 435–440.
22. Burns J, Bartholomew B, Lobo S. 1999. Isolation of myelin basic protein-specific T cells predominantly from the memory T-cell compartment in multiple sclerosis. Ann Neurol 45: 33–39.
23. Caramalho Í, Nunes-Cabaço H, Foxall RB, Sousa AE. 2015. Regulatory T-cell development in the human thymus. Front Immunol 6: 395.
24. Cencioni MT, Santini S, Ruocco G, Borsellino G, De Bardi M, Grasso MG, Ruggieri S, Gasperini C, Centonze D, Barilá D, et al. 2015. FAS-ligand regulates differential activation-induced cell death of human T-helper 1 and 17 cells in healthy donors and multiple sclerosis patients. Cell Death Dis 6: e1741.
25. Chalkias S, Dang X, Bord E, Stein MC, Kinkel RP, Sloane JA, Donnelly M, Ionete C, Houtchens MK, Buckle GJ, et al. 2014. JC virus reactivation during prolonged natalizumab monotherapy for multiple sclerosis. Ann Neurol 75: 925– 934.
26. Choi SS, Lee HJ, Lim I, Satoh J, Kim SU. 2014. Human astrocytes: Secretome profiles of cytokines and chemo-kines. PLoS ONE 9: e92325.
27. + regulatory T cells in multiple sclerosis. J Neuroimmunol 195: 121–134.
28. + T cells in multiple sclerosis revealed by novel flow cytometric assay. Blood 103: 4222–4231.
29. Damsker J, Hansen A, Caspi R. 2010. Th1 and Th17 cells: Adversaries and collaborators. Ann NY Acad Sci 1183: 211–221.
30. Dardalhon V, Korn T, Kuchroo VK, Anderson AC. 2008. Role of Th1 and Th17 cells in organ-specific autoimmunity. J Autoimmun 31: 252–256.
31. Debes GF, Arnold CN, Young AJ, Krautwald S, Lipp M, Hay JB, Butcher EC. 2005. Chemokine receptor CCR7 required for T lymphocyte exit from peripheral tissues. Nat Immunol 6: 889–894.
32. + T cells in multiple sclerosis. Expert Opin Ther Targets 17: 1053– 1066.
33. Dettke M, Scheidt P, Prange H, Kirchner H. 1997. Correlation between interferon production and clinical disease activity in patients with multiple sclerosis. J Clin Immunol 17: 293–300.
34. de Weerd NA, Nguyen T. 2012. The interferons and their receptors—Distribution and regulation. Immunol Cell Biol 90: 483–491.
35. Dressel A, Chin JL, Sette A, Gausling R, Hollsberg P, Hafler DA. 1997. Autoantigen recognition by human CD8 T cell clones: Enhanced agonist response induced by altered peptide ligands. J Immunol 159: 4943–4951.
36. Durelli L, Conti L, Clerico M, Boselli D, Contessa G, Ripel-lino P, Ferrero B, Eid P, Novelli F. 2009. T-helper 17 cells expand in multiple sclerosis and are inhibited by interferon-β. Ann Neurol 65: 499–509.
37. Durrenberger PF, Webb LV, Sim MJ, Nicholas RS, Altmann DM, Boyton RJ. 2012. Increased HLA-E expression in white matter lesions in multiple sclerosis. Immunology 137: 317–325.
38. Elain G, Jeanneau K, Rutkowska A, Mir AK, Dev KK. 2014. The selective anti-IL17A monoclonal antibody secukinu- mab (AIN457) attenuates IL17A-induced levels of IL6 in human astrocytes. Glia 62: 725–735.
39. H 17 cells is dependent on IL-1- and IL-23-induced production of the cytokine GM-CSF. Nat Immunol 12: 568–575.
40. Fink PJ, Hendricks DW. 2011. Post-thymic maturation: Young T cells assert their individuality. Nat Rev Immunol 11: 544–549.
41. Fletcher JM, Lalor SJ, Sweeney CM, Tubridy N, Mills KH. 2010. T cells in multiple sclerosis and experimental autoimmune encephalomyelitis. Clin Exp Immunol 162: 1–11.
42. Fogdell-Hahn A, Ligers A, Gronning M, Hillert J, Olerup O. 2000. Multiple sclerosis: A modifying influence of HLA class I genes in an HLA class II associated autoimmune disease. Tissue Antigens 55: 140–148.
43. + T cells in multiple sclerosis. Ann Neurol 66: 132–141.
44. Frischer JM, Bramow S, Dal-Bianco A, Lucchinetti CF, Rauschka H, Schmidbauer M, Laursen H, Sorensen PS, Lassmann H. 2009. The relation between inflammation and neurodegeneration in multiple sclerosis brains. Brain 132: 1175–1189.
45. Frisullo G, Nociti V, Iorio R, Patanella AK, Marti A, Caggiula M, Mirabella M, Tonali PA, Batocchi AP. 2008. IL17 and IFNγ production by peripheral blood mononuclear cells from clinically isolated syndrome to secondary progressive multiple sclerosis. Cytokine 44: 22–25.
46. Ganor Y, Teichberg VI, Levite M. 2007. TCR activation eliminates glutamate receptor GluR3 from the cell surface of normal human T cells, via an autocrine/paracrine granzyme B-mediated proteolytic cleavage. J Immunol 178: 683–692.
47. Gobin SJ, Montagne L, Van Zutphen M, Van Der Valk P, Van Den Elsen PJ, De Groot CJ. 2001. Upregulation of transcription factors controlling MHC expression in multiple sclerosis lesions. Glia 36: 68–77.
48. Goris A, Heggarty S, Marrosu MG, Graham C, Billiau A, Vandenbroeck K. 2002. Linkage disequilibrium analysis of chromosome 12q14-15 in multiple sclerosis: Delineation of a 118-kb interval around interferon-γ (IFNG) that is involved in male versus female differential susceptibility. Genes Immunity 3: 470–476.
49. Goverman JM. 2011. Immune tolerance in multiple sclerosis. Immunol Rev 241: 228–240.
50. Gross CC, Schulte-Mecklenbeck A, Rünzi A, Kuhlmann T, Posevitz-Fejfár A, Schwab N, Schneider-Hohendorf T, Herich S, Held K, Konjević M, et al. 2016. Impaired NK-mediated regulation of T-cell activity in multiple sclerosis is reconstituted by IL-2 receptor modulation. Proc Natl Acad Sci 113: E2973–E2982.
51. Harbo HF, Lie BA, Sawcer S, Celius EG, Dai KZ, Oturai A, Hillert J, Lorentzen AR, Laaksonen M, Myhr KM, et al. 2004. Genes in the HLA class I region may contribute to the HLA class II-associated genetic susceptibility to multiple sclerosis. Tissue Antigens 63: 237–247.
52. Harris MG, Hulseberg P, Ling C, Karman J, Clarkson BD, Harding JS, Zhang M, Sandor A, Christensen K, Nagy A, et al. 2014. Immune privilege of the CNS is not the consequence of limited antigen sampling. Sci Rep 4: 4422.
53. + Treg cells. Arthritis Rheum 63: 3153–3162.
54. Hauser SL, Bhan AK, Gilles F, Kemp M, Kerr C, Weiner HL. 1986. Immunohistochemical analysis of the cellular infiltrate in multiple sclerosis lesions. Ann Neurol 19: 578– 587.
55. Hayashi T, Morimoto C, Burks JS, Kerr C, Hauser SL. 1988. Dual-label immunocytochemistry of the active multiple sclerosis lesion: Major histocompatibility complex and activation antigens. Ann Neurol 24: 523–531.
56. Hedegaard CJ, Krakauer M, Bendtzen K, Lund H, Sellebjerg F, Nielsen CH. 2008. T helper cell type 1 (Th1), Th2 and Th17 responses to myelin basic protein and disease activity in multiple sclerosis. Immunology 125: 161–169.
57. Hickey WF, Kimura H. 1988. Perivascular microglial cells of the CNS are bone marrow-derived and present antigen in vivo. Science 239: 290–292.
58. Hirota K, Duarte JH, Veldhoen M, Hornsby E, Li Y, Cua DJ, Ahlfors H, Wilhelm C, Tolaini M, Menzel U, et al. 2011. Fate mapping of IL-17-producing T cells in inflammatory responses. Nat Immunol 12: 255–263.
59. + cytotoxic T lymphocytes restricted by HLA-A3: Evidence for cross-reactivity with an environmental microorganism. J Neuroimmunol 73: 7–14.
60. International Multiple Sclerosis Genetics Consortium; Well-come Trust Case Control Consortium 2; Sawcer S, Hellen-thal G, Pirinen M, Spencer CC, Patsopoulos NA, Moutsi-anas L, Dilthey A, Su Z, et al. 2011. Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature 476: 214–219.
61. + T cells in cerebrospinal fluid from multiple sclerosis patients. Brain 125: 538–550.
62. + T cells in early multiple sclerosis. Clin Immunol 123: 105–113.
63. Joffre OP, Segura E, Savina A, Amigorena S. 2012. Cross-presentation by dendritic cells. Nat Rev Immunol 12: 557– 569.
64. + regulatory T cells induced by an agonist self-peptide. Nat Immunol 2: 301–306.
65. Jung D, Alt FW. 2004. Unraveling V(D)J recombination. Cell 116: 299–311.
66. Junker A, Ivanidze J, Malotka J, Eiglmeier I, Lassmann H, Wekerle H, Meinl E, Hohlfeld R, Dornmair K. 2007. Multiple sclerosis: T-cell receptor expression in distinct brain regions. Brain 130: 2789–2799.
67. Kabat EA, Wolf A, Bezer AE. 1947. The rapid production of acute disseminated encephalomyelitis in rhesus monkeys by injection of heterologous and homologous brain tissue with adjuvants. J Exp Med 85: 117–130.
68. Kaiko GE, Horvat JC, Beagley KW, Hansbro PM. 2008. Immunological decision-making: How does the immune system decide to mount a helper T-cell response? Immunology 123: 326–338.
69. Kantarci OH, Goris A, Hebrink DD, Heggarty S, Cunningham S, Alloza I, Atkinson EJ, de Andrade M, McMurray CT, Graham CA, et al. 2005. IFNG polymorphisms are associated with gender differences in susceptibility to multiple sclerosis. Genes Immun 6: 153–161.
70. H 17 lymphocytes promote blood–brain barrier disruption and central nervous system inflammation. Nat Med 13: 1173–1175.
71. H 17 cells in multiple sclerosis. Ann Neurol 66: 390–402.
72. Kim IJ, Beck HN, Lein PJ, Higgins D. 2002. Interferon γ induces retrograde dendritic retraction and inhibits synapse formation. J Neurosci 22: 4530–4539.
73. Kish DD, Li X, Fairchild RL. 2009. CD8 T cells producing IL-17 and IFN-γ initiate the innate immune response required for responses to antigen skin challenge. J Immunol 182: 5949–5959.
74. Kostic M, Dzopalic T, Zivanovic S, Zivkovic N, Cvetanovic A, Stojanovic I, Vojinovic S, Marjanovic G, Savic V, Colic M. 2014. IL-17 and glutamate excitotoxicity in the pathogenesis of multiple sclerosis. Scand J Immunol 79: 181– 186.
75. Kostic M, Stojanovic I, Marjanovic G, Zivkovic N, Cvetanovic A. 2015. Deleterious versus protective autoimmunity in multiple sclerosis. Cell Immunol 296: 122–132.
76. Kuhlmann T, Lingfeld G, Bitsch A, Schuchardt J, Bruck W. 2002. Acute axonal damage in multiple sclerosis is most extensive in early disease stages and decreases over time. Brain 125: 2202–2212.
77. hi regulatory T cell-mediated suppression in patients with type 1 diabetes. Clin Exp Immunol 154: 353–359.
78. Leonardi CL, Kimball AB, Papp KA, Yeilding N, Guzzo C, Wang Y, Li S, Dooley LT, Gordon KB; PHOENIX 1 study investigators. 2008. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet 371: 1665–1674.
79. Lock C, Hermans G, Pedotti R, Brendolan A, Schadt E, Garren H, Langer-Gould A, Strober S, Cannella B, Allard J, et al. 2002. Gene-microarray analysis of multiple sclerosis lesions yields new targets validated in autoimmune encephalomyelitis. Nat Med 8: 500–508.
80. Longbrake EE, Racke MK. 2009. Why did IL-12/IL-23 antibody therapy fail in multiple sclerosis? Exp Rev Neuro-therapeut 9: 319–321.
81. Lovett-Racke AE, Trotter JL, Lauber J, Perrin PJ, June CH, Racke MK. 1998. Decreased dependence of myelin basic protein-reactive T cells on CD28-mediated costimulation in multiple sclerosis patients. A marker of activated/mem-ory T cells. J Clin Invest 101: 725–730.
82. Matusevicius D, Kivisäkk P, He B, Kostulas N, Ozenci V, Fredrikson S, Link H. 1999. Interleukin-17 mRNA expression in blood and CSF mononuclear cells is augmented in multiple sclerosis. Mult Scler 5: 101–104.
83. Mehling M, Lindberg R, Raulf F, Kuhle J, Hess C, Kappos L, Brinkmann V. 2010. Th17 central memory T cells are reduced by FTY720 in patients with multiple sclerosis. Neurology 75: 403–410.
84. Mingueneau M, Kreslavsky T, Gray D, Heng T, Cruse R, Ericson J, Bendall S, Spitzer MH, Nolan GP, Kobayashi K, et al. 2013. The transcriptional landscape of αβ T cell differentiation. Nat Immunol 14: 619–632.
85. H 17 cells in chronic inflammation. Nat Rev Drug Discov 11: 763–776.
86. Montes M, Zhang X, Berthelot L, Laplaud DA, Brouard S, Jin J, Rogan S, Armao D, Jewells V, Soulillou JP, et al. 2009. Oligoclonal myelin-reactive T-cell infiltrates derived from multiple sclerosis lesions are enriched in Th17 cells. Clin Immunol 130: 133–144.
87. Neumann H, Medana IM, Bauer J, Lassmann H. 2002. Cytotoxic T lymphocytes in autoimmune and degenerative CNS diseases. Trends Neurosci 25: 313–319.
88. Ni C, Wang C, Zhang J, Qu L, Liu X, Lu Y, Yang W, Deng J, Lorenz D, Gao P, et al. 2014. Interferon-γ safeguards blood–brain barrier during experimental autoimmune encephalomyelitis. Am J Pathol 184: 3308–3320.
89. + T cells is mediated through NKG2D, LFA-1 and TRAIL and dampened via CD94/NKG2A. PLoS ONE 7: e31959.
90. Olsson T. 1992. Cytokines in neuroinflammatory disease: Role of myelin autoreactive T cell production of interferon-γ. J Neuroimmunol 40: 211–218.
91. Olsson T, Zhi WW, Höjeberg B, Kostulas V, Jiang YP, Anderson G, Ekre HP, Link H. 1990. Autoreactive T lymphocytes in multiple sclerosis determined by antigen-in-duced secretion of interferon-γ. J Clin Invest 86: 981–985.
92. Onishi RM, Gaffen SL. 2010. Interleukin-17 and its target genes: Mechanisms of interleukin-17 function in disease. Immunology 129: 311–321.
93. O’Quinn DB, Palmer MT, Lee YK, Weaver CT. 2008. Emergence of the Th17 pathway and its role in host defense. Adv Immunol 99: 115–163.
94. Ottum PA, Arellano G, Reyes LI, Iruretagoyena M, Naves R. 2015. Opposing roles of interferon-γ on cells of the central nervous system in autoimmune neuroinflammation. Front Immunol 6: 539.
95. Panitch HS, Hirsch RL, Haley AS, Johnson KP. 1987a. Ex-acerbations of multiple sclerosis in patients treated with γ interferon. Lancet 1: 893–895.
96. Panitch HS, Hirsch RL, Schindler J, Johnson KP. 1987b. Treatment of multiple sclerosis with γ interferon: Exacer-bations associated with activation of the immune system. Neurology 37: 1097–1102.
97. Paterson PY. 1960. Transfer of allergic encephalomyelitis in rats by means of lymph node cells. J Exp Med 111: 119– 136.
98. Pelfrey CM, Rudick RA, Cotleur AC, Lee JC, Tary-Lehmann M, Lehmann PV. 2000. Quantification of self-recognition in multiple sclerosis by single-cell analysis of cytokine production. J Immunol 165: 1641–1651.
99. Peng H, Guerau-de-Arellano M, Mehta VB, Yang Y, Huss DJ, Papenfuss TL, Lovett-Racke AE, Racke MK. 2012. Dimethyl fumarate inhibits dendritic cell maturation via nuclear factor κB (NF-κB) and extracellular signal-regulated kinase 1 and 2 (ERK1/2) and mitogen stress-activat-ed kinase 1 (MSK1) signaling. J Biol Chem 287: 28017– 28026.
100. Perriard G, Mathias A, Enz L, Canales M, Schluep M, Gent-ner M, Schaeren-Wiemers N, Du Pasquier RA. 2015. In-terleukin-22 is increased in multiple sclerosis patients and targets astrocytes. J Neuroinflammation 12: 119.
101. Pinschewer DD, Schedensack M, Bergthaler A, Horvath E, Brück W, Löhning M, Merkler D. 2010. T cells can mediate viral clearance from ependyma but not from brain parenchyma in a major histocompatibility class I- and perforin-independent manner. Brain 133: 1054–1066.
102. Popko B, Baerwald KD. 1999. Oligodendroglial response to the immune cytokine interferon γ. Neurochem Res 24: 331–338.
103. Ramgolam VS, Sha Y, Jin J, Zhang X, Markovic-Plese S. 2009. IFN-β inhibits human Th17 cell differentiation. J Immunol 183: 5418.
104. Ransohoff RM, Estes ML. 1991. Astrocyte expression of major histocompatibility complex gene products in multiple sclerosis brain tissue obtained by stereotactic biopsy. Arch Neurol 48: 1244–1246.
105. Rivers TM, Schwentker FF. 1935. Encephalomyelitis accompanied by myelin destruction experimentally produced in monkeys. J Exp Med 61: 689–702.
106. Rivers TM, Sprunt DH, Berry GP. 1933. Observations on attempts to produce acute disseminated encephalomyelitis in monkeys. J Exp Med 58: 39–53.
107. Rolla S, Bardina V, De Mercanti S, Quaglino P, De Palma R, Gned D, Brusa D, Durelli L, Novelli F, Clerico M. 2014. Th22 cells are expanded in multiple sclerosis and are resistant to IFN-β. J Leukocyte Biol 96: 1155–1164.
108. Sakaguchi S, Wing K, Miyara M. 2007. Regulatory T cells—A brief history and perspective. Eur J Immunol 37: S1.
109. Salinas S, Schiavo G, Kremer EJ. 2010. A hitchhiker’s guide to the nervous system: The complex journey of viruses and toxins. Nat Rev Microbiol 8: 645–655.
110. Sallusto F, Lenig D, Forster R, Lipp M, Lanzavecchia A. 1999. Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature 401: 708–712.
111. Sandborn WJ, Feagan BG, Fedorak RN, Scherl E, Fleisher MR, Katz S, Johanns J, Blank M, Rutgeerts P; Ustekinumab Crohn’s Disease Study Group. 2008. A randomized trial of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with moderate-to-severe Crohn’s disease. Gastroenterology 135: 1130–1141.
112. Sawcer S, Ban M, Maranian M, Yeo TW, Compston A, Kirby A, Daly MJ, De Jager PL, Walsh E, Lander ES, et al. 2005. A high-density screen for linkage in multiple sclerosis. Am J Hum Genet 77: 454–467.
113. + regulatory T cells. J Immunol 181: 7350–7355.
114. Schneider A, Long SA, Cerosaletti K, Ni CT, Samuels P, Kita M, et al. 2013. In active relapsing-remitting multiple sclerosis, effector T cell resistance to adaptive Tregs involves IL-6–mediated signaling. Sci Transl Med 5: 170ra15.
115. Schwentker FF, Rivers TM. 1934. The antibody response of rabbits to injections of emulsions and extracts of homologous brain. J Exp Med 60: 559–574.
116. Segal BM, Constantinescu CS, Raychaudhuri A, Kim L, Fi-delus-Gort R, Kasper LH; Ustekinumab MS Investigators. 2008. Repeated subcutaneous injections of IL12/23 p40 neutralising antibody, ustekinumab, in patients with relapsing-remitting multiple sclerosis: A phase II, double-blind, placebo-controlled, randomised, dose-ranging study. Lancet Neurol 7: 796–804.
117. H 2 hypothesis of T cell-mediated tissue damage. Nat Med 13: 139–145.
118. Stritesky GL, Jameson SC, Hogquist KA. 2012. Selection of self-reactive T cells in the thymus. Annu Rev Immunol 30: 95–114.
119. Sun JB, Olsson T, Wang WZ, Xiao BG, Kostulas V, Fredrikson S, Ekre HP, Link H. 1991. Autoreactive T and B cells responding to myelin proteolipid protein in multiple sclerosis and controls. Eur J Immunol 21: 1461–1468.
120. Sweeney CM, Lonergan R, Basdeo SA, Kinsella K, Dungan LS, Higgins SC, Kelly PJ, Costelloe L, Tubridy N, Mills KH, et al. 2011. IL-27 mediates the response to IFN-β therapy in multiple sclerosis patients by inhibiting Th17 cells. Brain Behav Immun 25: 1170–1181.
121. Tan CS, Koralnik IJ. 2010. Progressive multifocal leukoence-phalopathy and other disorders caused by JC virus: Clinical features and pathogenesis. Lancet Neurol 9: 425–437.
122. Tauhid S, Neema M, Healy BC, Weiner HL, Bakshi R. 2014. MRI phenotypes based on cerebral lesions and atrophy in patients with multiple sclerosis. J Neurol Sci 346: 250– 254.
123. The Lenercept Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group. 1999. TNF neutralization in MS: Results of a randomized, placebo-controlled multicenter study. Neurology 53: 457– 465.
124. Traugott U, Lebon P. 1988a. Multiple sclerosis: Involvement of interferons in lesion pathogenesis. Ann Neurol 24: 243–251.
125. Traugott U, Lebon P. 1988b. Interferon-γ and Ia antigen are present on astrocytes in active chronic multiple sclerosis lesions. J Neuro Sci 84: 257–264.
126. Traugott U, Reinherz EL, Raine CS. 1983. Multiple sclerosis. Distribution of T cells, T cell subsets and Ia-positive mac- rophages in lesions of different ages. J Neuroimmunol 4: 201–221.
127. + T-cell responses to human myelin protein-derived peptides. Proc Natl Acad Sci 91: 10859–10863.
128. Tzartos JS, Friese MA, Craner MJ, Palace J, Newcombe J, Esiri MM, Fugger L. 2008. Interleukin-17 production in central nervous system-infiltrating T cells and glial cells is associated with active disease in multiple sclerosis. Am J Pathol 172: 146–155.
129. Tzartos JS, Craner MJ, Friese MA, Jakobsen KB, Newcombe J, Esiri MM, Fugger L. 2011. IL-21 and IL-21 receptor expression in lymphocytes and neurons in multiple sclerosis brain. Am J Pathol 178: 794–802.
130. Vaknin-Dembinsky A, Balashov K, Weiner HL. 2006. IL-23 is increased in dendritic cells in multiple sclerosis and down-regulation of IL-23 by antisense oligos increases dendritic cell IL-10 production. J Immunol 176: 7768.
131. H 1) functional phenotype of human myelin basic protein-specific T lymphocytes. Autoimmunity 15: 137–143.
132. Walker LSK. 2009. Regulatory T cells overturned: The effec-tors fight back. Immunology 126: 466–474.
133. Wehrens EJ, Mijnheer G, Duurland CL, Klein M, Meerding J, van Loosdregt J, de Jager W, Sawitzke B, Coffer PJ, Vastert B, et al. 2011. Functional human regulatory T cells fail to control autoimmune inflammation due to PKB/c-akt hyperactivation in effector cells. Blood 118: 3538.
134. Williams KA, Hart DN, Fabre JW, Morris PJ. 1980. Distribution and quantitation of HLA-ABC and DR (Ia) antigens on human kidney and other tissues. Transplantation 29: 274–279.
135. Wingerchuk DM, Carter JL. 2014. Multiple sclerosis: Current and emerging disease-modifying therapies and treatment strategies. Mayo Clin Proc 89: 225–240.
136. + T cells in the patients with neuromyelitis optica and multiple sclerosis. J Neuroimmunol 261: 87–91.
137. Yao Z, Spriggs MK, Derry JM, Strockbine L, Park LS, Van-denBos T, Zappone JD, Painter SL, Armiage RJ. 1997. Molecular characterization of the human interleukin (IL)-17 receptor. Cytokine 9: 794–800.
138. + cytotoxic T cell responses to myelin basic protein in multiple sclerosis. J Immunol 172: 5120–5127.
139. Zhu J, Yamane H, Paul WE. 2010. Differentiation of effector CD4 T cell populations. Ann Rev Immunol 28: 445–489.